PIC Therapeutics
A biotechnology company focused on fundamentally changing how people treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation.
Related Content
PIC Therapeutics is a biotechnology company revolutionizing cancer treatment by developing precision-based therapeutics that target cancer signaling pathways. The company focuses on selectively blocking oncogene protein production by modulating the Pre Initiation Complex (PIC) that drives mRNA translation. This approach has the potential to simultaneously modulate multiple oncogenic drivers, offering a powerful new generation of cancer treatments. PIC Therapeutics serves patients with unmet medical needs, particularly those who have developed resistance to existing therapies or face complex tumor progression. The company operates in the biotechnology and pharmaceutical markets, primarily targeting oncology. Its business model involves the research and development of small molecule precision therapeutics, which are then brought to market either through direct commercialization or partnerships with larger pharmaceutical companies. Revenue is generated through product sales, licensing agreements, and potential milestone payments from partners.
Keywords: biotechnology, cancer treatment, RNA translation, oncogene, precision therapeutics, mRNA modulation, oncology, small molecule, therapeutic resistance, pharmaceutical.